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Abstract  Article Info 
Introduction: Nasopharyngeal Papillary Adenocarcinoma (NPAC) is a very rare type of nasopharyngeal cancer. 
NPAC was distinguished from common nasopharyngeal cancer due to its specific histological type. 
Case Report: We reported a case of a 58-year-old male patient with complaints of headache, mass in the 
nasopharynx, and lumps on both sides of the neck. Based on his history of illness, physical examination, 
imaging, and histopathology, we concluded that he was diagnosed with Nasopharyngeal Papillary 
Adenocarcinoma (NPAC). Six cycles of paclitaxel-cisplatin chemotherapy regimen were planned for the patient. 
The patient was currently undergoing his fifth cycle of chemotherapy and showed a good response. 
Conclusion: The chemotherapy management of this patient was given according to the general management of 
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1. CASE REPORT 
A 58-year-old male was referred to Dr Kariadi Central Hospital in April 
2019. He complained of intermittent headaches, blurred vision in both eyes, 
tinnitus in the right ear, reduced hearing in the right ear, obstruction in both 
noses (especially the right nose), nosebleeds and lumps on both sides of the 
neck. These complaints had been felt since the previous five months. He had 
a previous history of thyroid cancer treatment, diagnosed in 2001 according to 
the histopathology results. The result showed that he had a well-differentiated 
follicular adenocarcinoma of thyroid. He had undergone eight cycles of 
ablation therapy in 2001 and 2018. In 2017, he had undergone 33 cycles of 
external radiation at Dr Sardjito Central Hospital. On September 6th, 2019, he 
had undergone 35 cycles of external radiation at Dr Kariadi Central Hospital. 
The patient underwent laboratory tests to determine the thyroglobulin and 
TSHs levels, which concluded that there was no metastatic tissue of thyroid 
cancer in other parts of the body. He was then declared to achieve complete 
clinical remission by his physician. 
Furthermore, the patient underwent an anterior rhinoscopy, which showed 
a mass invading the right nasal cavity. The mass looked brittle and bleeding 
easily. Meanwhile, it was difficult to assess the left nasal cavity. Neck 
examination showed a lump on the left neck (2 x 1 x 1 cm), which had solid 
consistency, fixed structure, and the same colour as its surrounding tissues. 
 
 
Picture 1. Flexible nasopharyngoscopy on April 15th, 2019 
Flexible nasopharyngoscopy on April 15th, 2019, showed a mass in the 
upper-posterior nasopharynx extending into the right and left nasal cavity. 
The mass looked brittle and bleeding easily. We performed biopsy in three 
areas on the right nasal cavity.  
On April 22nd, 2019, the patient came to the ENT outpatient clinic of Dr 
Kariadi Central Hospital for his follow-up. He brought his histopathology 
result, which showed non-specific inflammation and the presence of 
malignancies that could not be excluded. We referred him to an 
ophthalmologist, who advised to do an MRI of the head with contrast. 
 
 
(a)                         (b) 
Picture 2. The result of the MRI of the head with contrast on April 29th, 
2019. (a) axial view; (b) sagittal view. 
On April 29th, 2019, we performed an MRI with contrast at Dr Kariadi 
Central Hospital, which showed a lobulated lesion in the nasopharynx 
extending to the middle fossa, cavernous sinus, clivus, sella turcica, nasal 
cavity, right maxillary sinus, ethmoid sinus, sphenoid sinus, and the right 
frontal sinus. The lesion also invaded the medial wall of the orbital cavity, 
medial rectus muscle, the canalicular segment of the optic nerve, optic 
chiasma, occipital condyles, and dens of the axis (± AP 11.2 x CC 7.22 x 
5.37 cm). The differential diagnosis was nasopharyngeal mass, clival 
chordoma, sinonasal mass, and left frontal and maxillary sinusitis. We re-
consulted the MRI results to an ophthalmologist. The patient was diagnosed 
with early papilledema in the right eye, and nasopharyngeal mass infiltrating 
the orbital cavities. The ophthalmologist prescribed him with 
Chloramphenicol eye ointment for every 8 hours, and 0.5% of Timolol eye 
drops for every 12 hours. 
On May 7th, 2019, we performed another biopsy on the patient under 
general anesthesia. The histopathological result showed tissue debris 
covered with squamous and pseudostratified epithelium, sub-epithelial 







stroma, swelling, hyperemia, with extensive bleeding and necrosis. Within 
the debris, there were groups of cells with oval round and hyperchromatic 
nuclei, eosinophilic cytoplasm, and pleomorphic nuclei. It also showed a 
mitosis process. Some of them were glandular with papillary foci 
accompanied by inflammatory cells called lymphocytes, 
polymorphonuclear leukocytes, and histiocytes. The result concluded that it 
was Nasopharyngeal Papillary Adenocarcinoma. 
We performed cancer staging by performing the chest x-ray, abdominal 
ultrasound, audiometry and ECG. On May 27th, 2019, we conducted audio 
tympanometry at the Clinical Diagnostic Center (CDC) of Dr Kariadi 
Central Hospital. The examination showed that there was mild sensorineural 
hearing loss (SNHL) in the right ear with a PTA of 32.5 dB. In the left ear, 
the test was normal with PTA of 15 dB. The tympanometry result showed 
that the right ear belonged to type A and the left ear belonged to type Ad. On 
May 31st, 2019, we performed the posteroanterior chest x-ray and abdominal 
ultrasound and found no abnormalities or metastatic features. 
 
 
Picture 3. MSCT with contrast of nasopharynx on November 7th, 2019 
(compared to the result of April 29th, 2019) 
We compared the MSCT with a contrast of the Nasopharynx result, 
performed on November 7th, 2019, to the MRI of the head result, performed 
on April 29th, 2019. The results showed a nasopharyngeal mass with vascular 
structures within, extending to the parapharyngeal space, sphenoid sinus, 
ethmoid sinus, maxillary sinus, frontal sinus, and nasal cavity. The mass also 
infiltrated intracranially into the middle fossa of the sellar and suprasellar 
region. It attached to the lateral pterygoid muscle, invaded the optic nerve, and 
the medial rectus muscle. Furthermore, it also attached to the intracanalicular 
part of the optic nerve, pressed on the cavernous sinus, and obliterated the 
ostiomeatal complex, and nasal concha. We also found destructions of the 
ethmoid, sphenoid, and maxillary sinus walls, right sphenoid wing, sella 
turcica, clivus, cribriform plate, and right petrous part of the temporal bone. 
There was also proptosis of the right and left ocular bulbs, which was relatively 
reduced compared to the previous result (±AP 8.37 cm x LL 7.51 cm x CC 
6.65 cm vs ±11.2 cm x LL 5.37 cm x CC 7.22 cm). Finally, there was 
lymphadenopathy at the right neck region of level 2.5 and left neck region of 
level 5 (largest size of ±1.07 cm x 0.49 cm), appropriate to T4N2Mx. 
We planned to prescribe him with chemotherapy using paclitaxel cisplatin 
regimen (6 cycles). On December 21st, 2019, during his first cycle of 
chemotherapy, he complained of a slight headache and nausea. He showed 
good condition after undergoing chemotherapy and was subsequently 
discharged and prescribed with oral medicine for his home treatment. Until 
recently, he has been undergoing five cycles of chemotherapy and shows good 
condition, despite experiences occasional nausea and malaise. He was 
supposed to undergo his sixth cycle of chemotherapy, but it was delayed due 
to the current pandemic situation. 
2. DISCUSSION 
Nasopharyngeal papillary adenocarcinoma (NPAC) is a rare neoplasm, 
distinguished from the common nasopharyngeal carcinoma by its specific 
histological type. The characteristics of NPAC are slow growth rate, a 
tendency for an invasion of cranial nerves, high recurrence rate, and distant 
metastases [1]. In this case, there was an invasion of the canalicular segment 
of the right and left optic nerve, as well as the optic chiasma. 
The incidence of nasopharyngeal papillary adenocarcinoma (NPAC) is 
very rare, which is less than 0.5% of nasopharyngeal malignancies. NPAC 
was first described by Wenig et al. in 1988 [2,3]. It occurs over a wide age 
range from the first to seventh decades of life, and shows an almost equal 
gender distribution (1:1). Patients present with symptoms of nasal 
obstruction and epistaxis. Most tumors are located in the posterior and 
lateral walls of nasopharynx, and on the nasopharyngeal roof, where they 
occur as nodular or polypoid exophytic growths [4, 5]. In this case, we 
reported a 58- year-old man who had complaints of nasal congestion and 
nosebleeds. 
 
2.1  Pathophysiology 
The etiology of nasopharyngeal papillary adenocarcinoma (NPAC) is 
not yet known. However, some previous literature described that, like the 
common nasopharyngeal carcinoma, the etiology was multifactorial. These 
factors include genetic factors, Epstein Barr virus (EBV) infection, 
smoking, alcohol, and exposure to carcinogens [6]. 
In 2005, the World Health Organization (WHO) made a classification 
of the head and neck tumours. They classified malignant epithelial 
neoplasms of the nasopharynx into these following three categories: 
nasopharyngeal carcinoma, salivary gland type carcinoma, and 
nasopharyngeal papillary adenocarcinoma (NPAC) [7]. 
Based on histopathology, the characteristics of NPAC are papillary 
configuration with a fibrovascular nucleus hyaline similar to those found in 
papillary thyroid carcinoma. Furthermore, there was a dense glandular 
structure, lined with cuboidal or round columnar epithelium, overlapping 
with fine chromatin and light eosinophilic cytoplasm, or papillary thyroid 
carcinoma-shaped epithelium [8]. 
Based on microscopic examination, NPAC is indistinguishable from the 
thyroid papillary adenocarcinoma. NPAC is immunoreactive against thyroid 
transcription factor (TTF-1), which plays an important role in cell 
differentiation and thyroid gland morphogenesis. NPAC may be a primary 
tumour of the nasopharynx or metastasis from the thyroid gland. Because 
primary NPAC is very rare, it is important to exclude the presence of 
nasopharyngeal metastases from thyroid papillary adenocarcinoma 
[9,10,11]. 
NPAC can emerge either from the mucosal surface, salivary glands, or the 
thyroid gland (a metastatic form). NPAC usually involves the roof of the 
nasopharynx and lateral or posterior walls of the nasopharynx. It is described 
as exophytic with a polypoid or nodular structure. The histological findings of 
NPAC are very similar to those of papillary thyroid carcinoma [12]. 
2.1  Diagnosis 
NPAC has a clinical presentation that does not differ greatly from 
nasopharyngeal malignancy. In general, patients with nasopharyngeal 
tumours often experience at least four symptoms, including nose symptoms 
(epistaxis, nasal obstruction), a lump of the neck, ear symptoms (tinnitus, 
deafness/hearing loss), and cranial symptoms (headache or nerve palsy) 
[13]. In this case, the patient complained of hoarseness, nasal obstruction, 
and intermittent headaches. Furthermore, he also experienced an impaired 
vision in his both eyes, tinnitus in the right ear, and a lump on the left neck. 
We also found a mass in the upper posterior nasopharynx, extending to the 
right and left nasal cavity. The mass looked brittle and bleeding easily. 
The staging system of NPAC is similar to those of common 
nasopharyngeal carcinoma. The 2020 National Comprehensive Cancer 
Network (NCCN) guideline is used for the most recent staging system of 
head and neck malignancies [14]. 
Table 1. Tumour in Nasopharynx (T) 
Tx Primary tumour cannot be assessed 
T0 No identified tumour, but positive cervical EBV involvement 
Tis Carcinoma in situ 
T1 Tumour is limited in nasopharynx or expands to oropharynx / nasal cavity without any 
expansion to parapharyngeal space 
T2 Tumour with expansion to parapharyngeal space or adjacent soft tissue involvement 
(medial pterygoid, lateral pterygoid, and prevertebral muscles) 
T3 Tumour erodes the bone and or paranasal sinuses 
T4 Tumour expands intracranially and or invades the cranial nerves, infratemporal fossa, 
hypopharynx or orbit, parotid gland, and / or extensive soft tissue infiltration outside 
the surface of lateral pterygoid muscle. 
Table 2. Lymph Nodes 
Nx Regional lymph nodes cannot be determined 
N0 No metastasis to regional lymph nodes 
N1 Metastasis to unilateral regional lymph nodes, with the size of 6 cm or less, above the 
caudal margin of cricoid cartilage 
N2 Metastasis to bilateral regional lymph nodes, with the size of 6 cm or less, above the 
caudal margin of cricoid cartilage 
N3 Metastasis to the lymph nodes of the cervix unilaterally or bilaterally, with the largest 
size of more than 6 cm, and / or extension to the area under the margin of cricoid 
cartilage 







Table 3. Distant Metastasis  
M0 No distant metastasis 
M1 Distant metastasis 
Table 4. Staging  
Staging 0 Tis N0 M0 
Staging I T1 N0 M0 




































Staging IVB  Any T Any N M1 
2.2 Treatment 
Treatment and prognosis of nasopharyngeal cancer depend on the type 
of tissue, histological characteristics, and TNM staging. A study found that 
nasopharyngeal adenocarcinoma with low morphic grade and clear 
hyalinization had a good prognosis. Patients with such tumours can survive 
and are free from recurrence or metastasis [15]. 
The management of NPAC is similar to those of common nasopharyngeal 
carcinoma, which is radiotherapy and chemotherapy. Therefore, surgery is not 
the first choice for tumour localization. Radiotherapy alone can lead to 
complete remission during its early stages, while radiotherapy in combination 
with chemotherapy is the main treatment for advanced tumours. Due to the 
rarity of nasopharyngeal adenocarcinoma cases, no standard treatment has 
been established. In developed countries, elective surgical excision and 
radiotherapy are recommended as an operative treatment for patients at high 
risk of postoperative recurrences [16]. 
Previous authors recommended radiotherapy for nasopharyngeal 
malignancies. Wang et al. reported 20 patients with nasopharyngeal adenoid 
cystic carcinoma who received definitive radiotherapy. The five-year local 
control rate was 45.5%, while the five-year and ten-year survival rates were 
78 and 49.5%, respectively. Radiation-induced damage to normal tissue can 
be minimized more precisely with the 3D conformal radiation therapy. 
Intensity-modulated radiation therapy (IMRT) has been reported to improve 
local control and also minimize radiation-induced parotid damage. On the 
other hand, high linear energy transfer (LET) radiation therapy may help 
improve the outcome [17,18,19].  
During the operative procedure, we must pay attention to the structure of the 
nasopharynx, which has a complex anatomy. It is surrounded by various vital 
tissues and organs, including the brain stem, spinal cord, and cranial nerves. 
Therefore, sometimes complete resection is difficult to achieve [6, 20]. 
There have been no reports of NPAC-specific chemotherapy. However, 
several reports confirmed that this tumour was sensitive to 5-Fluorouracil 
and anthracyclines, which appeared to be effective. Some combinations of 
effective therapeutic regimens include cisplatin, 5-fluorouracil, and CAP 
(cyclophosphamide, doxorubicin and cisplatin). However, reported 
chemotherapy response rates from the literature varied [17]. The CAP 
regimen has been showing the most consistent outcomes and reported 
response rates are 25-33% [20]. 
In this case, the patient was given paclitaxel cisplatin regimen (6 
cycles). After the fifth cycle of chemotherapy, the patient experienced relief 
in his symptoms. He somehow felt other complaints, such as occasional 
nausea. However, due to the current pandemic condition, he postponed his 
sixth cycle of chemotherapy. 
3. CONCLUSION 
We reported a case of a 58-year-old male with stage IVA 
Nasopharyngeal papillary adenocarcinoma (T4N2M0) who underwent 
chemotherapy with five cycles of paclitaxel cisplatin chemotherapy regimen 
with good response.  
NPAC is a rare cancer, but it presents clinical challenges in its 
treatment, diagnosis and classification. The rarity of this cancer makes its 
evaluation very difficult. Therefore, it is necessary to understand the 
characteristics of various types of sub-pathology and histology to provide 
an accurate and optimal clinical evaluation in treatment. 
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